user
menu
letter
Sign InRegister
langEnglisharrow

Biotinylated Human HLA-A*24:02&B2M&NY-ESO-1 (LLMWITQCF) Complex Protein (Monomer, MALS verified)

Cat. No. / Size
Price
Availability
Qty
HL1-H82E3-25ug
$125.00
In Stock - Delivery in 1-2 business days
HL1-H82E3-200ug
$700.00
In Stock - Delivery in 2-3 weeks
HL1-H82E3
Sub-Total :
$ 0
Customize Product Request Quote
Contact Us
Contact Us
Sub-Total:
$ 0
Request Quote
Product Details
Performance Data
Reviews & Citations
Resources
  • Product Details
  • Performance Data
  • Reviews & Citations
  • Important Statement
  • Resources
Synonyms

HLA-A*2402 & B2M & NY-ESO-1 (LLMWITQCF)

Source

Biotinylated Human HLA-A*24:02&B2M&NY-ESO-1 (LLMWITQCF) Complex Protein (HL1-H82E3) is expressed from human 293 cells (HEK293). It contains AA Gly 25 - Thr 305 (HLA-A*24:02) & Ile 21 - Met 119 (B2M) & LLMWITQCF peptide (Accession # AAA59600.1 (HLA-A*24:02) & P61769 (B2M) & LLMWITQCF).

Predicted N-terminus: Gly 25 & Ile 21

Molecular Characterization

Biotinylated Human HLA-A*24:02&B2M&NY-ESO-1 (LLMWITQCF) Complex Protein is produced by co-expression of HLA and B2M loaded with NY-ESO-1 peptide.

This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

The protein has a calculated MW of 35.8 kDa and 11.7 kDa. The protein migrates as 38-42 kDa and <14 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

Labeling

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Purity

>90% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

Formulation

Supplied as 0.2 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Shipping and Storage

This product is supplied and shipped on dry ice.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • The product MUST be stored at -70°C or lower upon receipt;
  • -70°C for 3 months under sterile conditions.
ACRO Quality Management System

Background

NY-ESO-1, which is also well-known as New York esophageal squamous cell carcinoma 1, is an efficient target for cancer immunotherapy. This antigen is a member of cancer-testis antigens (CTAs) and is highly expressed in various cancers, including melanoma, ovarian, cervical cancer, etc. Adoptive T cell therapy with HLA-A24 restricted NY-ESO-1 transduced CD8+ T cells has improved the clinical response rates and overall survival of treatment-refractory melanoma patients. The Human HLA-A*2402 NY-ESO-1 (LLMWITQCF) complex protein is a complex of HLA-A*2402 of the MHC Class I, B2M and LLMWITQCF peptide of the NY-ESO-1.